Cvrx, Inc. ( (CVRX) ) has released its Q4 earnings. Here is a breakdown of the information Cvrx, Inc. presented to its investors.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
CVRx, Inc. is a commercial-stage medical device company specializing in neuromodulation solutions for cardiovascular diseases, notably its Barostim system, which is an implantable device approved by the FDA for heart failure treatment.
The company’s earnings report for the fourth quarter and full year of 2024 highlights substantial revenue growth, particularly in the U.S. heart failure segment, reflecting a strong market presence and the achievement of key reimbursement milestones.
CVRx reported a 36% year-over-year increase in quarterly revenue, totaling $15.3 million, with U.S. heart failure revenue rising by 41%. The company expanded its active implanting centers to 223, marking a 25% increase from the previous year. Despite revenue growth, CVRx faced a net loss of $10.7 million for the quarter, attributed to increased SG&A expenses and higher interest costs.
For the full year, CVRx achieved a revenue of $51.3 million, up 31% from 2023, while maintaining a gross margin of 84%. The company’s strategic priorities for 2025 include enhancing its sales organization, increasing Barostim’s utilization, and overcoming adoption barriers.
Looking forward, CVRx anticipates continued revenue growth, projecting total revenue between $63.0 million and $65.0 million for 2025, with a focus on solidifying Barostim as a standard care option in heart failure treatment.
